Innovation Management

Appreciating the value of science

By creating the new position of Chief Innovation Officer (CIO), the German Cancer Research Center is helping to ensure that research results find their way to clinical application – and to commercialization – more often and faster. The position has been filled by Rainer Wessel, an established expert with 25 years of experience as a manager in the pharmaceutical and biotechnology sector.

New Career Planning Tool of DKFZ


CareerCheck is an internet-based career advice and career planning tool for young scientists at the German Cancer Research Center. It complements the existing career services such as guidance talks, trainings, Career Days and the internet platform dkfz-connect.


Ana Banito awarded for her research on soft tissue sarcomas

Ana Banito, scientist at the German Cancer Research Center (DKFZ) and the Hopp Children's Cancer Center Heidelberg" (KiTZ) received the Award of the Berlin-Brandenburg Academy of Sciences and Humanities for her work on sarcomas, a group of malignant tumors which is quite common in children. The prize, donated by the Monika Kutzner Foundation and endowed with 10,000 euros, is awarded annually for special achievements that advance cancer research.

We are asking for your support

Your Donation for Cancer Research
Latest News

How dying cells prevent dangerous immune reactions

Dying cells in the body can keep the immune system in check, thus preventing unwanted immune responses against the body's own tissues. Scientists of the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) have now identified a receptor on immune cells that activates this protective mechanism. This prevents dangerous autoimmune reactions in which the immune system is directed against the body's own structures, as the researchers have now been able to show in mice and human cells.

Deadline 15 March 2020

Are you considering a career as a clinician scientist?

Apply for a prestigious two-year DKFZ Clinician Scientist Fellowship! More Information here.


Search for research topic

Latest News

Ursula Weyrich succeeds Josef Puchta as Administrative Director of DKFZ

As of January 1, 2020, Ursula Weyrich will take over as Administrative Director of the German Cancer Research Center (DKFZ). Weyrich will succeed Josef Puchta, who reached the legal retirement age on November 30 after more than 23 years on the Management Board at DKFZ.

Latest News

3D atlas of the bone marrow - in single cell resolution

Stem cells located in the bone marrow generate and control the production of blood and immune cells. Researchers from EMBL, DKFZ and HI-STEM have now jointly developed new methods to reveal the three-dimensional organization of the bone marrow at the single cell level. Using this approach the teams have identified previously unknown cell types that create specific local environments required for blood generation from stem cells. The study, published in Nature Cell Biology, reveals an unexpected complexity of the bone marrow and its microdomains at an unprecedented resolution and provides a novel scientific basis to study blood diseases such as leukemias.

Latest News

Armed antibodies for cancer immunotherapy: DKFZ and DKTK scientists granted patent for innovative antibody design

Scientists from the German Cancer Consortium (DKTK) and the German Cancer Research Center (DKFZ) at Tübingen University Hospital have managed to attach immunostimulatory cytokines to cancer-specific antibodies for the first time in such a way that they activate the immune response against cancer without causing a dangerous overreaction by the immune system. The research team has now been granted a European patent for the method to enable them to produce the modified cytokines on a large scale and subsequently test them in clinical trials. A license and cooperation agreement has been signed with the South Korean biotech company ABL Bio on the production of two substances of clinical quality.

Latest News

Metabolic adaptation ensures survival of colon cancer cells

Colon cancer cells deficient in p53, one of the most important control proteins in cell growth, activate a particular metabolic pathway to adapt to the lack of oxygen and nutrients inside the tumor. Statins, which are often prescribed to lower cholesterol, block this metabolic pathway and cause the cancer cells to die, as scientists from the German Cancer Research Center (DKFZ) have now discovered. The researchers now intend to investigate this potential treatment strategy in more detail in cancer cells and animal experiments.

DKFZ - A Video

to top